keyword
MENU ▼
Read by QxMD icon Read
search

Immuno oncology

keyword
https://www.readbyqxmd.com/read/29773327/immuno-oncology-in-malignant-pleural-mesothelioma
#1
Paul Baas, Maria Disselhorst
No abstract text is available yet for this article.
May 14, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29764163/onward-and-upward-for-immuno-oncology
#2
Malcolm K Brenner
No abstract text is available yet for this article.
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29764158/what-is-the-role-of-immunotherapy-in-breast-cancer
#3
Tira J Tan, Jack J Chan, Sulastri Kamis, Rebecca Alexandra Dent
The immune system plays a complex role in the recognition/prevention, early eradication as well as progression of cancer. Recently, we have witnessed great momentum in the field of immuno-oncology. Checkpoint inhibitors and chimeric antigen receptor T cell therapy have now entered the clinic, with impressive and durable clinical responses seen across a broad array of tumor types. There are several lines of evidence supporting the development of an immune targeted approach in breast cancer. Emerging data of early clinical trials evaluating monotherapy checkpoint inhibition have shown modest activity in breast cancer, in particular high grade and aggressive subtypes such as triple negative, human epidermal growth factor receptor 2 (HER2)-positive and luminal B breast cancers...
April 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29758241/targeting-the-cd73-adenosine-axis-in-immuno-oncology
#4
REVIEW
David Allard, Pavel Chrobak, Bertrand Allard, Nouredin Messaoudi, John Stagg
The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis. With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses. With early-phase clinical trials showing promising results, it is becoming increasingly important to decipher the distinct mechanisms-of-action of adenosine-targeting agents, identify patients that will benefit from these agents and rationally develop novel synergistic combinations...
May 11, 2018: Immunology Letters
https://www.readbyqxmd.com/read/29754777/international-validation-of-the-consensus-immunoscore-for-the-classification-of-colon-cancer-a-prognostic-and-accuracy-study
#5
Franck Pagès, Bernhard Mlecnik, Florence Marliot, Gabriela Bindea, Fang-Shu Ou, Carlo Bifulco, Alessandro Lugli, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Y Wang, P Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Mihaela Angelova, Angela Vasaturo, Pauline Maby, Sarah E Church, Helen K Angell, Lucie Lafontaine, Daniela Bruni, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Jeffrey P Meyers, Christopher Paustian, Zipei Feng, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Daniel J Sargent, Bernard A Fox, Jérôme Galon
BACKGROUND: The estimation of risk of recurrence for patients with colon carcinoma must be improved. A robust immune score quantification is needed to introduce immune parameters into cancer classification. The aim of the study was to assess the prognostic value of total tumour-infiltrating T-cell counts and cytotoxic tumour-infiltrating T-cells counts with the consensus Immunoscore assay in patients with stage I-III colon cancer. METHODS: An international consortium of 14 centres in 13 countries, led by the Society for Immunotherapy of Cancer, assessed the Immunoscore assay in patients with TNM stage I-III colon cancer...
May 10, 2018: Lancet
https://www.readbyqxmd.com/read/29754509/-new-and-traditional-directions-in-the-biology-and-management-of-childhood-acute-lymphoblastic-leukemia
#6
Bálint Egyed, Gábor Kovács, Nóra Kutszegi, Andrea Rzepiel, Judit Csányiné Sági, Dániel János Erdélyi, Judit Müller, Ágnes Félné Semsei
Owing to clinical trials and improvement over the past few decades, the majority of children with acute lymphoblastic leukemia (ALL) survive by first-line chemotherapy and combat with the problems of returning to community. However, many patients may have severe acute or late therapeutic side effects, and the survival rate in some groups (e.g., patients with MLL rearrangements, hypodiploidy, IKZF1 mutation or early precursor T cell phenotype) is far behind the average. Innovative strategies in medical attendance provide better clinical outcomes for them: complete gene diagnostics, molecularly targeted anticancer treatment, immuno-oncology and immune cell therapy...
May 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29748871/an-introduction-to-recent-trends-in-the-biotechnology-industry-development-and-manufacturing-of-recombinant-antibodies-and-proteins
#7
Michael Pohlscheidt, Robert Kiss, Uwe Gottschalk
The production of the first therapeutic proteins in the early 1980s heralded the launch of the biopharmaceuticals industry. The number of approved products has grown year on year over the past three decades to now represent a significant share of the entire pharmaceuticals market. More than 200 therapeutic proteins have been approved, approximately a quarter of which are represented by monoclonal antibodies and their derivatives. In 2016, the list of the top 15 best-selling drugs included more than eight biologics and in 2020 the trend will continue, with more than 50% of the top 20 best-selling drugs predicted to be biologics...
May 11, 2018: Advances in Biochemical Engineering/biotechnology
https://www.readbyqxmd.com/read/29748739/anticalin-%C3%A2-proteins-as-therapeutic-agents-in-human-diseases
#8
REVIEW
Christine Rothe, Arne Skerra
Anticalin proteins are an emerging class of clinical-stage biopharmaceuticals with high potential as an alternative to antibodies. Anticalin molecules are generated by combinatorial design from natural lipocalins, which are abundant plasma proteins in humans, and reveal a simple, compact fold dominated by a central β-barrel, supporting four structurally variable loops that form a binding site. Reshaping of this loop region results in Anticalin proteins that can recognize and tightly bind a wide range of medically relevant targets, from small molecules to peptides and proteins, as validated by X-ray structural analysis...
May 10, 2018: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29734296/cytokine-resurrection-engineered-il-2-ramps-up-immuno-oncology-responses
#9
Ken Garber
No abstract text is available yet for this article.
May 9, 2018: Nature Biotechnology
https://www.readbyqxmd.com/read/29714652/real-world-evidence-in-metastatic-renal-cell-carcinoma
#10
Jeffrey Graham, Daniel Yc Heng
Real-world evidence has played an important role in expanding our knowledge on the treatment and prognostication of advanced renal cell carcinoma. This type of data has been particularly helpful in providing a better understanding of groups that are traditionally excluded from randomized controlled trials. The International mRCC Database Consortium (IMDC) represents the largest collection of real-world data on patients with advanced kidney cancer treated with targeted therapies. The IMDC prognostic model has been used to stratify patients in contemporary clinical trials and to provide risk-directed treatment selection in everyday clinical practice...
March 1, 2018: Tumori
https://www.readbyqxmd.com/read/29714118/prediction-of-response-to-targeted-and-immune-checkpoint-therapies
#11
Edward D Blair, Martina Kaufmann, Mieke Keppens
Targeted therapies continue to be key components of cancer treatment. New approaches to detection of acquired resistance at the genomic level, in combination with new therapies, help to overcome the challenges that are seen frequently, rapidly and broadly across tumor pathologies, and provide opportunities for cancer management. In the last several years, a new breed of modalities called immune checkpoint inhibitors have come to the forefront of clinically effective treatments. A plethora of rapid approvals and early access initiatives have seen anti-cytotoxic T-lymphocyte-associated antigen-4, and particularly anti-programmed death receptor-1 therapies, deployed in a number of tumor indications of high unmet need...
January 2018: Personalized Medicine
https://www.readbyqxmd.com/read/29708143/combination-immuno-oncology-therapy-with-immune-checkpoint-blockers-targeting-pd-l1-pd-1-or-ctla4-and-epigenetic-drugs-targeting-myc-and-immune-evasion-for-precision-medicine
#12
EDITORIAL
https://www.readbyqxmd.com/read/29704931/-novel-strategy-in-oncoimmunology
#13
REVIEW
François Ghiringhelli
Recent advances in immuno-oncology with the development of anti-PD1/PD-L1 antibodies are revolutionizing oncological management. Immuno-oncology I currently developing in most histological types of cancer. However, the rate of success of anti-PD1/PD-L1 antibodies in monotherapy is limited by a limited to a subpopulation of patients accounting for about 25-30 % of patients in most indications. The development of new strategies is based on this observation with the aim to predict response or enhancing response rate...
April 25, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29704129/integrative-pharmacology-advancing-development-of-effective-immunotherapies
#14
Mohammad Tabrizi, Daping Zhang, Vaishnavi Ganti, Glareh Azadi
With the recent advances in cancer immunotherapy, it is now evident that the antigen-specific activation of the patients' immune responses can be utilized for achieving significant therapeutic benefits. Novel molecules have been developed and promising advances have been achieved in cancer therapy. The recent success of cancer immunotherapy clearly reflects the novelty of the approach and importance of this class of therapeutics. Due to the nature of immunotherapy, i.e., harnessing the patient's immune system, it becomes critical to evaluate the important variables that can guide preclinical development, translational strategies, patient selection, and effective clinical dosing paradigms following single and combination therapies...
April 27, 2018: AAPS Journal
https://www.readbyqxmd.com/read/29703766/immuno-oncology-biomarkers-for-gastric-and-gastroesophageal-junction-adenocarcinoma-why-pd-l1-testing-may-not-be-enough
#15
Benjamin A Weinberg, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, Mohamed E Salem, John L Marshall
PURPOSE: The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD-L1) protein by companion diagnostic testing. However, some patients with PD-L1-negative tumors also benefit from pembrolizumab. High microsatellite instability (MSI) and tumor mutational load (TML) are positive predictive biomarkers for immune checkpoint inhibition (ICI) in other tumors...
April 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29681201/cost-effectiveness-vs-affordability-in-the-age-of-immuno-oncology-cancer-drugs
#16
George Dranitsaris, Xiaofu Zhu, Georges Adunlin, Mark D Vincent
After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as 'Immuno-oncology' (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor-associated antigens. Areas covered: Clinical trials have demonstrated the effectiveness of several IO agents in many disease sites such as early and advanced stage melanoma, advanced non-small cell lung cancer, bladder, head and neck, gastric, kidney as well as Hodgkin's lymphoma...
April 25, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29681156/fluorescent-labeled-selective-adenosine-a2b-receptor-antagonist-enables-competition-binding-assay-by-flow-cytometry
#17
Meryem Köse, Sabrina Gollos, Tadeusz Karcz, Amelie Fiene, Fabian Heisig, Andrea Behrenswerth, Katarzyna J Kiec-Kononowicz, Vigneshwaran Namasivayam, Christa E Müller
Fluorescent ligands represent powerful tools for biological studies and are considered as attractive alternatives to radioligands. In this study, we developed fluorescent antagonists for A2B adenosine receptors (A2BARs), which are targeted by anti-asthmatic xanthines and were proposed as novel targets in immuno-oncology. Our approach was to merge a small BODIPY derivative with the pharmacophore of 8-substituted xanthine derivatives. Based on the design, synthesis and evaluation of model compounds several fluorescent ligands were synthesized...
April 22, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29670099/nuclear-receptor-nr2f6-inhibition-potentiates-responses-to-pd-l1-pd-1-cancer-immune-checkpoint-blockade
#18
Victoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, Bojana Jakic, Anne Offermann, Mirjana Efremova, Sieghart Sopper, Dietmar Rieder, Anne Krogsdam, Gabriele Gamerith, Sven Perner, Alexandar Tzankov, Zlatko Trajanoski, Dominik Wolf, Gottfried Baier
Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progression and improves survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of Nr2f6 alone or together with PD-L1 blockade reveal multiple advantageous transcriptional alterations...
April 18, 2018: Nature Communications
https://www.readbyqxmd.com/read/29664561/the-function-and-dysfunction-of-memory-cd8-t-cells-in-tumor-immunity
#19
REVIEW
James L Reading, Felipe Gálvez-Cancino, Charles Swanton, Alvaro Lladser, Karl S Peggs, Sergio A Quezada
The generation and maintenance of CD8+ T cell memory is crucial to long-term host survival, yet the basic tenets of CD8+ T cell immunity are still being established. Recent work has led to the discovery of tissue-resident memory cells and refined our understanding of the transcriptional and epigenetic basis of CD8+ T cell differentiation and dysregulation. In parallel, the unprecedented clinical success of immunotherapy has galvanized an intense, global research effort to decipher and de-repress the anti-tumor response...
May 2018: Immunological Reviews
https://www.readbyqxmd.com/read/29656021/next-generation-neuro-oncology
#20
REVIEW
Michael Weller
Neuro-oncology has evolved as a growing, but still small, highly specialised and multidisciplinary field at the interface of several diagnostic and therapeutic disciplines. The major challenge in the field of primary tumours is to translate the almost unique progress in deciphering the highly complex molecular genetic nature of many primary brain tumours, notably glioblastoma, into advances that allow for clinical benefit for affected patients. Furthermore, metastases to the central nervous system are an increasingly prevalent complication in many systemic cancers...
April 12, 2018: European Journal of Cancer
keyword
keyword
36927
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"